Patents by Inventor Yunxiao Li
Yunxiao Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11949087Abstract: A method for preparing a graphene-coated powder material, comprising: A) dispersing a graphene powder and/or graphene oxide powder, a powder material to be coated with graphene, and a polymeric co-coating agent in a first organic solvent to form a first organic solvent dispersion; B) mixing the first organic solvent dispersion with a second organic solvent and separating a precipitate after sedimentation; and C) annealing the precipitate in an inert atmosphere to obtain the graphene-coated powder material; wherein the polymeric co-coating agent is soluble in the first organic solvent but insoluble in the second organic solvent. The present invention also relates to a graphene-coated powder material prepared by the method.Type: GrantFiled: May 31, 2017Date of Patent: April 2, 2024Assignees: BEIJING TUNGHSU CARBON ADVANCED MATERIALS TECHNOLOGY CO., LTD., TUNGHSU GROUP CO., LTD.Inventors: Qing Li, Yunxiao Tong, Heran Li, Zhonghui Wang
-
Publication number: 20230211708Abstract: A seat slide device includes a pair of sliders each including a fixed rail, a movable rail slidably guided by the fixed rail, a bracket on the movable rail configured so that front and rear sides swing opposite to each other in a vertical direction with a longitudinal-intermediate part as a fulcrum, a support bracket supported on the bracket via a hinge and configured to rotate in only one direction from a predetermined orientation about an lateral-direction axis relative to the bracket, a movement-restricting portion configured to restrict sliding of the movable rail while a rear part of the bracket is raised and to release the restriction while the rear part of the bracket is lowered; and a towel bar connecting each support bracket. The hinge part prohibits a rotation of the support bracket while the towel bar is lifted and permits the rotation while the towel bar is lowered.Type: ApplicationFiled: December 30, 2021Publication date: July 6, 2023Inventors: Motohiko Ozawa, Naoto Komiya, Atsunori Matsui, Yunxiao Li, Laxmikant Indi, Frederick L. Wilkinson, Sean M. Osinski, Valentin Muresan, Wenting Zhang
-
Publication number: 20230052348Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: ApplicationFiled: October 14, 2021Publication date: February 16, 2023Applicant: AMGEN INC.Inventors: Sean P BROWN, David Karl BEDKE, Michael R. DEGRAFFENREID, Jiasheng FU, Zhinghong LI, Felix GONZALEZ LOPEZ DE TURISO, Ana GONZALEZ BUENROSTRO, Michael W. GRIBBLE JR., Michael G. JOHNSON, Todd J. KOHN, Kexue LI, Yunxiao LI, Mike Elias LIZARZABURU, Yosup REW, Joshua TAYGERLY, Yingcai WANG, Xuelei YAN, Ming YU, Jiang ZHU, Manuel ZANCANELLA, Xian Yun JIAO, Liusheng ZHU, Xianghong WANG, Julio C. MEDINA, Jason A. DUQUETTE, Jonathan B. HOUZE, Marc VIMOLRATANA, Mario G. CARDOZO, Alan C. CHENG
-
Patent number: 11364248Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: GrantFiled: August 17, 2018Date of Patent: June 21, 2022Assignee: AMGEN INC.Inventors: Sean P. Brown, Kexue Li, Yunxiao Li, Anthony B. Reed, Brian Alan Lanman
-
Patent number: 11306107Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: GrantFiled: February 24, 2017Date of Patent: April 19, 2022Assignee: AMGEN INC.Inventors: Sean P. Brown, David Karl Bedke, Michael R. Degraffenreid, Jiasheng Fu, Zhihong Li, Felix Gonzalez Lopez De Turiso, Ana Gonzalez Buenrostro, Michael W. Gribble, Jr., Michael G. Johnson, Todd J. Kohn, Kexue Li, Yunxiao Li, Mike Elias Lizarzaburu, Yosup Rew, Joshua Taygerly, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu, Manuel Zancanella, Xian Yun Jiao, Liusheng Zhu, Xianghong Wang, Julio C. Medina, Jason A. Duquette, Jonathan B. Houze, Marc Vimolratana, Mario G. Cardozo, Alan C. Cheng
-
Patent number: 11279712Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stenoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: GrantFiled: August 27, 2018Date of Patent: March 22, 2022Assignee: AMGEN INC.Inventors: Sean P. Brown, Yunxiao Li, Paul E. Harrington, Brian Alan Lanman, Jonathan D. Low, Ana Elena Minatti, Vu Van Ma, Kexue Li
-
Patent number: 11273743Abstract: A mat mounting structure for mounting a mat on a seat back frame in a seat back may have a guide wire attachable to the mat configured to receive a force from a back of an occupant on the seat back. The guide wire may have a straight part extending linearly in a longitudinal direction of the seat back frame on a head side or a root side of the seat back frame. A bushing including a penetration hole in which the straight part is insertable in the longitudinal direction may be included in the structure. An attachment hole part in the seat back frame may also be part of the structure. The bushing may be detachably engageable with and attachable to the attachment hole part.Type: GrantFiled: December 22, 2020Date of Patent: March 15, 2022Assignees: Adient Engineering and IP GmbH, Honda Motor Co., Ltd.Inventors: Frederick L. Wilkinson, Sean M. Osinski, Yunxiao Li, Wenting Zhang, Naoto Komiya, Laxmikant Indi, Toshimitsu Mizukoshi, Taiji Misono, Hiroki Ikeda, Hiromitsu Nagatomo, Yuki Fukuda, Souhei Noguchi
-
Patent number: 11224601Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: GrantFiled: September 23, 2020Date of Patent: January 18, 2022Assignee: AMGEN INC.Inventors: Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn, Brian Alan Lanman, Kexue Li, Yunxiao Li, Jonathan D. Low, Ana Elena Minatti, Alexander J. Pickrell, Markian M. Stec, Joshua Taygerly
-
Publication number: 20210230189Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: ApplicationFiled: February 24, 2017Publication date: July 29, 2021Applicant: AMGEN INC.Inventors: Sean P. BROWN, David Karl BEDKE, Micheal R. DEGRAFFENREID, Jiasheng FU, Zhihong LI, Felix GONZALEZ LOPEZ TURISO, Ana GONZALEZ BUENROSTRO, Micheal W. GRIBBLE, JR., Micheal G. JOHNSON, Todd J. KOHN, Kexue LI, Yunxiao LI, Mike Elias LIZARZABURU, Yosup REW, Joshua TAYGERLY, Yingcal WANG, Xuelei YAN, Ming YU, Jiang ZHU, Manuel ZANCANELLA, Xian Yun JIAO, Liusheng ZHU, Xianghong WANG, Julio C. MEDINA, Jason A. DUQUETTE, Jonathan B. HOUZE, Marc VIMOLRATANA, Marlo G. CARDOZO, Alan C. CHENG
-
Publication number: 20200360399Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: ApplicationFiled: August 17, 2018Publication date: November 19, 2020Applicant: AMGEN INC.Inventors: Sean P. BROWN, Kexue LI, Yunxiao LI, Anthony B. REED, Brian Alan LANMAN
-
Patent number: 10836779Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: GrantFiled: September 5, 2018Date of Patent: November 17, 2020Assignee: AMGEN INC.Inventors: Sean P. Brown, Yunxiao Li, Mike Elias Lizarzaburu, Brian S. Lucas, Nick A. Paras, Joshua Taygerly, Marc Vimolratana, Xianghong Wang, Ming Yu, Manuel Zancanella, Liusheng Zhu, Ana Gonzalez Buenrostro, Zhihong Li
-
Patent number: 10821115Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: GrantFiled: February 6, 2020Date of Patent: November 3, 2020Assignee: AMGEN INC.Inventors: Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn, Brian Alan Lanman, Kexue Li, Yunxiao Li, Jonathan D. Low, Ana Elena Minatti, Alexander J. Pickrell, Markian M. Stec, Joshua Taygerly
-
Publication number: 20200247821Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stenoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: ApplicationFiled: August 27, 2018Publication date: August 6, 2020Applicant: AMGEN INC.Inventors: Sean P. BROWN, Yunxiao LI, Paul E. HARRINGTON, Brian Alan LANMAN, Jonathan D. LOW, Ana Elena MINATTI, Vu Van MA, Kexue LI
-
Publication number: 20200171043Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: ApplicationFiled: February 6, 2020Publication date: June 4, 2020Applicant: AMGEN INC.Inventors: Paul E. HARRINGTON, Kate ASHTON, Sean P. BROWN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Yunxiao LI, Jonathan D. LOW, Ana Elena MINATTI, Alexander J. PICKRELL, Markian M. STEC, Joshua TAYGERLY
-
Patent number: 10632128Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: GrantFiled: August 22, 2019Date of Patent: April 28, 2020Assignee: AMGEN INC.Inventors: Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn, Brian Alan Lanman, Kexue Li, Yunxiao Li, Jonathan D. Low, Ana Elena Minatti, Alexander J. Pickrell, Markian M. Stec, Joshua Taygerly
-
Publication number: 20200062780Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: ApplicationFiled: September 13, 2019Publication date: February 27, 2020Applicant: Amgen Inc.Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S. LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
-
Publication number: 20190381064Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: ApplicationFiled: August 22, 2019Publication date: December 19, 2019Applicant: AMGEN INC.Inventors: Paul E. HARRINGTON, Kate ASHTON, Sean P. BROWN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Yunxiao LI, Jonathan D. LOW, Ana Elena MINATTI, Alexander J. PICKRELL, Markian M. STEC, Joshua TAYGERLY
-
Patent number: 10500213Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: GrantFiled: March 11, 2019Date of Patent: December 10, 2019Assignee: AMGEN INC.Inventors: Sean P. Brown, Kexue Li, Yunxiao Li, Markian M. Stec
-
Publication number: 20190201412Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: ApplicationFiled: March 11, 2019Publication date: July 4, 2019Applicant: AMGEN INC.Inventors: Sean P. Brown, Kexue Li, Yunxiao Li, Markian M. Stec
-
Patent number: 10300075Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: GrantFiled: March 28, 2018Date of Patent: May 28, 2019Assignee: AMGEN INC.Inventors: Sean P. Brown, Kexue Li, Yunxiao Li, Markian M. Stec